Bharat Book Bureau Provides the Trending Industry Research Report on“Global Radiopharmaceuticals in Nuclear Medicine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028”under Life Sciences Market Research Report. The report offers a collection of superior Market research, Market analysis, competitive intelligence and Market reports.

Executive Summary

The Radiopharmaceuticals in Nuclear Medicine Market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.


According to our  latest study, due to COVID-19 pandemic, the global Radiopharmaceuticals in Nuclear Medicine market size is estimated to be worth US$ 4943.7 million in 2021 and is forecast to a readjusted size of USD 6857.2 million by 2028 with a CAGR of 4.8% during review period. Diagnostic Application accounting for % of the Radiopharmaceuticals in Nuclear Medicine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Diagnostic Radiopharmaceuticals segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Radiopharmaceuticals in Nuclear Medicine include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, and Eczacibasi-Monrol, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Radiopharmaceuticals in Nuclear Medicine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes

Market segment by Application can be divided into
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other

The key market players for global Radiopharmaceuticals in Nuclear Medicine market are listed below:
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Radiopharmaceuticals in Nuclear Medicine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Radiopharmaceuticals in Nuclear Medicine, with price, sales, revenue and global market share of Radiopharmaceuticals in Nuclear Medicine from 2019 to 2022.
Chapter 3, the Radiopharmaceuticals in Nuclear Medicine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Radiopharmaceuticals in Nuclear Medicine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Radiopharmaceuticals in Nuclear Medicine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Radiopharmaceuticals in Nuclear Medicine.
Chapter 13, 14, and 15, to describe Radiopharmaceuticals in Nuclear Medicine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Browse our full report with Table of Content : https://www.bharatbook.com/report/1337934/global-radiopharmaceuticals-in-nuclear-medicine-market-by-manufacturers-regions-type-and-application-forecast-to

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 15,00,000 reports and insights that includes latest Industry Study, Industry Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com